Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sonelokimab,Adalimumab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody® M1095 (sonelokimab) by using SHL Medical's market-proven Molly® modular platform technology.
Brand Name : M1095
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 03, 2023
Lead Product(s) : Sonelokimab,Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?